ASC amino-acid transporter 2 (ASCT2) as a novel prognostic marker in non-small cell lung cancer

Abstract

Background:

ASC amino-acid transporter 2 (ASCT2) is a major glutamine transporter that has an essential role in tumour growth and progression. Although ASCT2 is highly expressed in various cancer cells, the clinicopathological significance of its expression in non-small cell lung cancer (NSCLC) remains unclear.

Methods:

One hundred and four patients with surgically resected NSCLC were evaluated as one institutional cohort. Tumour sections were stained by immunohistochemistry (IHC) for ASCT2, Ki-67, phospho-mTOR (mammalian target of rapamycin), and CD34 to assess the microvessel density. Two hundred and four patients with NSCLC were also validated by IHC from an independent cohort.

Results:

ASC amino-acid transporter 2 was expressed in 66% of patients, and was closely correlated with disease stage, lymphatic permeation, vascular invasion, CD98, cell proliferation, angiogenesis, and mTOR phosphorylation, particularly in patients with adenocarcinoma (AC). Moreover, two independent cohorts confirmed that ASCT2 was an independent marker for poor outcome in AC patients.

Conclusions:

ASC amino-acid transporter 2 expression has a crucial role in the metastasis of pulmonary AC, and is a potential molecular marker for predicting poor prognosis after surgery.

Lung cancer is the leading cause of cancer deaths worldwide. Therefore, assessing the potential of established biomarkers for predicting the outcome and the response to specific therapies is important to improve the prognosis of patients with non-small cell lung cancer (NSCLC). Tumour staging and performance status are currently the most powerful prognostic predictors in patients with NSCLC (Brundage et al, 2002). Recent large-scale studies demonstrated that sex, smoking history, and histology could affect the prognosis after treatment in patients with NSCLC, especially in adenocarcinoma (AC) (Kawaguchi et al, 2010; Nakamura et al, 2011; Kogure et al, 2013). Performance status and disease staging are generally known factors associated with prognosis after treatment.

ASC amino-acid transporter 2 (ASCT2) is a Na⁺-dependent transporter responsible for the transport of neutral amino acids, including glutamine, leucine, and isoleucine (Kekuda et al, 1996). It is the major glutamine transporter in human hepatoma cells (Fuchs et al, 2007), and has a role in tumour growth and the proliferation of cancer cells (Fuchs and Bode, 2006). It is highly expressed in various malignancies, including hepatocellular carcinoma and colorectal or prostate cancer, and its expression is closely associated with tumour aggressiveness and prognosis in colorectal or prostate cancer (Whitte et al, 2002; Li et al, 2003; Fuchs et al, 2007). It provides cancer cells with essential amino acids for protein synthesis, and it coordinates tumour cell growth through the activation of mammalian target of rapamycin (mTOR) (Fuchs et al, 2007). Glutamine promotes cancer cell proliferation and has a high affinity for ASCT2 (Fuchs and Bode, 2006; Fuchs et al, 2007). Amino-acid transporters are essential for the growth and survival of tumour cells, and L-type amino-acid transporter 1 (LAT1) also has a crucial role in the development and proliferation of transformed cells (Kanai et al, 1998; Yanagida et al, 2001; Kaira et al, 2008, 2012). It is an L-type amino-acid transporter that transports large neutral amino acids, such as leucine, isoleucine, valine, phenylalanine, tyrosine, tryptophan, methionine, and histidine (Kanai et al, 1998; Yanagida et al, 2001). It requires a covalent association with the heavy chain of 4F2 cell-surface antigen (CD98) for its functional expression and localisation in the plasma membrane (Kanai et al, 1998; Yanagida et al, 2001). Recent studies have focussed on ASCT2 and LAT1, which are highly expressed in cancer cells (Fuchs and Bode, 2006). The overexpression of LAT1 may be a significant predictor of poor prognosis, and it is closely linked to the aggressiveness and metastasis of various human neoplasms (Nawashiro et al, 2006; Nakanishi et al, 2007; Kaira et al, 2008, 2012; Sakata et al, 2009; Ichinoe et al, 2011; Furuya et al; 2012). Although the clinical importance of LAT1 expression in cancer cells is understood, the clinicopathological significance of ASCT2 expression in human neoplasms remains unclear. We therefore conducted a clinicopathological study to investigate the expression of ASCT2 in tissue specimens of resected NSCLC. The aim of our study was to clarify whether the expression of ASCT2 was closely associated with the outcome after treatment and to explore the relationship between ASCT2 and clinical characteristics. In addition, the correlation between ASCT2 expression and CD98, the Ki-67 labelling index (LI), microvessel density (MVD) (determined by CD34), and the phosphorylation of mTOR (p-mTOR) was assessed.

Materials and methods

Patients

We analysed 111 consecutive patients with NSCLC who underwent resection either by lobectomy or pneumonectomy with mediastinal lymph-node dissection at Nishigunma National Hospital (NGH, Shibukawa, Japan) between July 2007 and January 2010. Of these patients, 7 were excluded from further analysis because tissue specimens were not available; thus, 104 patients were enrolled in the study. Postoperative adjuvant chemotherapy with platinum-based regimens, S-1 (Taiho Pharmaceutical Co., Ltd, Tokyo, Japan) and oral administration of tegafur (a fluorouracil derivative drug) were administered to 19, 1, and 12 patients, respectively. No chemotherapy or radiotherapy before surgery was performed on any patient. The study protocol was approved by the institutional review board. The tumour specimens were histologically classified according to World Health Organisation criteria. The stages of pathological tumour-node-metastasis were established using the International System for Staging Lung Cancer adopted by the American Joint Committee on Cancer and the Union Internationale Centre le Cancer (Mountain, 1997). The day of surgery was considered to be the first day after surgery. The follow-up duration ranged from 139 to 2118 days (median, 1362 days).

For validation, we analysed an independent series of patients with NSCLC who underwent complete resection of the primary lung tumour with mediastinal lymph-node dissection at Gunma University Hospital (GUH, Maebashi, Japan) between June 2003 and June 2008. The median follow-up period was 1932 days (range, 160–3765 days).

Immunohistochemical staining

The protocol used for immunohistochemistry (IHC) is described elsewhere (Kaira et al, 2008, 2012). An oligopeptide (RDSKGLAAAEPTAN), corresponding to amino acids 7–20 of ASCT2 (1 : 300 dilution), was used to synthesise rabbit polyclonal antibodies, as described previously (Altman et al, 1984). The N-terminal cysteine residue was used for conjugation to keyhole limpet haemocyanin. The antiserum was affinity purified as described previously (Chairoungdua et al, 2001), and the specificity was confirmed (Supplementary Procedures). Briefly, HEK293T cells were transfected with a plasmid encoding ASCT2 or empty vector control. Crude membrane fractions were isolated, separated by SDS–PAGE, and analysed by western blotting as described by Khunweeraphong et al (2012). Immunohistochemistry was performed on paraffin sections using the polymer peroxidase method (Histofine Simple Stain MAX PO (MULTI) kit; Nichirei Corp., Tokyo, Japan). Briefly, deparaffinised and rehydrated sections were treated with 0.3% hydrogen peroxide (H₂O₂) in methanol for 30 min to block endogenous peroxidase activity. To expose the antigens, sections were autoclaved in ethylenediaminetetraacetic acid (pH 8.0) for 5 min and cooled for 30 min. After rinsing in phosphate-buffered saline, the sections were incubated with affinity-purified anti-ASCT2 antibodies (1 : 300) overnight followed by immunohistochemical staining with a Histofine Simple Stain MAX PO (MULTI) kit (Nichirei Corp.). The peroxidase reaction was carried out using 0.02% 3,3′-diaminobenzidine tetrahydrochloride and 0.01% H₂O₂ in 0.05 M Tris–HCl (pH 7.4). Negative control tissue sections were stained as described above, except that the primary antibody was omitted.

Anti-CD98 is an affinity-purified rabbit polyclonal antibody (1 : 100 dilution; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) raised against a C-terminal peptide of human CD98. ASC amino-acid transporter 2 and CD98 staining was considered as positive only if distinct membrane staining was detected. The ASCT2 and CD98 expression scores were assessed by the extent of staining as follows: 1, ⩽10% of the tumour area stained; 2, 11–25% 3, 26–50% and 4, ⩾51% stained. Those tumours with a score of >2 were considered to have a high level of expression.

Mouse monoclonal antibodies against CD34 (1 : 800 dilution; Nichirei Corp.) and Ki-67 (1 : 40; Dako, Glostrup, Denmark), and a rabbit monoclonal antibody against p-mTOR (1 : 80; Cell Signaling Technology, Danvers, MA, USA) were also used. The number of CD34-positive vessels was counted in four randomly selected regions in a × 400 field (0.26 mm² field area). The MVD was defined as the mean number of microvessels per 0.26 mm² field area, and tumours in which the number of stained tumour cells was greater than the median were defined as high expressors. For Ki-67, epithelial cells with nuclear staining of any intensity were considered to be positive. Approximately 1000 nuclei were counted on each slide, and the proliferative activity was assessed as the percentage of Ki-67-stained nuclei (Ki-67 LI) in each sample. The median Ki-67 LI was evaluated, and tumours with an LI greater than the median were considered to be positive. For p-mTOR, a semiquantitative scoring method was used: 1, <10% 2, 10–25% 3, 25–50% and 4, ⩾51% of positive cells. Those tumours with a staining score of >3 were considered to be strongly stained (Kaira et al, 2008, 2012). All sections were independently assessed using light microscopy in a blinded manner by at least two of the authors.

Statistical analysis

P-values<0.05 were used to indicate a statistically significant difference. Fisher's exact test was used to examine the association between two categorical variables. The correlation between different variables was analysed using the non-parametric Spearman's rank test. ASC amino-acid transporter 2 expression score was correlated with other immunohistochemical measurements and clinical variables. Since the sample size of NGH was not enough to do multivariate analysis using many prognostic variables; sex, smoking, stage, and histology which are known factors as described above were selected for the analysis. We added ASCT2 to these variables, and multivariate analysis was performed. In GUH cohort, we did multivariate analysis using the same prognostic variables.

Elderly patients were defined as more than 65 years old, and an ever smoker was defined as someone who had smoked at least 100 cigarettes in his lifetime. Disease staging was divided into two groups; stage I or II (early disease) and stage III or IV (advanced disease). The Kaplan–Meier method was used to estimate survival as a function of time, and survival differences were analysed by the log-rank test. Overall survival (OS) was determined as the time from tumour resection to death from any cause. Progression-free survival (PFS) was defined as the time between tumour resection and the first disease progression or death. Multivariate analyses were performed using a stepwise Cox proportional hazards model to identify independent prognostic factors. Statistical analyses were performed using JMP 8 for Windows (SAS Institute Inc., Cary, NC, USA).

Results

Immunohistochemical analysis and clinicopathological features

One hundred and four primary lung cancer lesions were analysed by IHC. Figure 1 shows representative staining for ASCT2. Expression of ASCT2 was detected in carcinoma cells in tumour tissues, and it was localised predominantly on the plasma membrane. All positive cells showed strong membrane staining. High levels of ASCT2 and CD98 expression were observed in 63% (66 out of 104) and 55% (55 out of 104) of the tumours, respectively. When staining was correlated with histological type, a statistically significant difference in ASCT2 staining was observed between patients with AC (55%: 36 out of 66) and non-AC (79%: 30 out of 38) (P=0.019). The median number of CD34-positive vessels was 16 (range, 1–41); thus, 16 was chosen as the cutoff to define a high expression level. The median Ki-67 LI was 17% (range, 1–82), so 17% was selected to define high-level expression. High levels of expression of CD34 and Ki-67 LI were detected in 45% (47 out of 104) and 44% (46 out of 104) of the tumours, respectively. A total of 39% (41 out of 104) of the tumours exhibited high-level expression of p-mTOR.

Figure 1.

Immunohistochemical staining of tumour tissue from a 68-year-old male with a pulmonary SQC (A) and a 70-year-old female with a pulmonary AC (B). ASCT2 exhibited a membranous immunostaining pattern (A, score of 4; B, score of 3).

The clinicopathological features of the patients are shown in Table 1. In the NGH cohort, 28 squamous cell carcinomas (SQCs), 6 large cell carcinomas, and 4 NSCLCs were detected in those patients without AC. In the GUH cohort, all non-AC patients presented with SQC, and the positive expression of ASCT2 was significantly higher in SQC compared with AC (70% vs 40%, P<0.001). A statistically significant difference in lymphatic permeation, vascular invasion, and ASCT2, CD98, and p-mTOR staining was observed between the NGH and GUH cohorts.

Table 1. Demographics and clinical characteristics of the patients.

Variables	NGH cohort (n=104)	GUH cohort (n=204)	P-value
Age
⩽65 years	31	67	0.607
>65 years	73	137
Sex
Male	64	119	0.624
Female	40	85
Smoking
Yes	66	126	0.805
No	38	78
p-Stage
I or II	80	159	0.658
III or IV	24	41
T factor
T1-2	93	177	0.585
T3-4	11	27
N factor
N0	71	143	0.795
N1-2	33	61
Histology
AC	66	142	0.304
Non-AC	38	62
Lymphatic permeation
Positive	59	87	0.022
Negative	45	117
Vascular invasion
Positive	57	72	0.001
Negative	47	132
ASCT2
High	66	101	0.022
Low	38	103
CD98
High	57	68	<0.001
Low	47	136
Ki-67
High	46	90	>0.999
Low	58	114
CD34
High	47	69	0.062
Low	57	135
p-mTOR
High	41	56	0.038
Low	63	148

Abbreviations: AC=adenocarcinoma; ASCT2=ASC amino-acid transporter 2; GUH=Gunma University Hospital; NGH=Nishi-Gunma Hospital; non-AC=non-adenocarcinoma; p-mTOR=phosphorylation of mammalian target of rapamycin.

Bold entries show statistically significant difference.

Patient characteristics based on ASCT2 expression

Table 2 shows the characteristics of the tumours in the NGH cohort. In all patients (n=104), positive ASCT2 expression was significantly associated with being male, having an advanced-stage tumour, T factor, lymph-node metastasis, non-AC, lymphatic permeation, vascular invasion, CD98, Ki-67 LI, and MVD (assessed by CD34 staining). Positive histological staining for ASCT2 in the AC patients was significantly associated with the above variables in addition to p-mTOR, but only with Ki-67 LI in the non-AC patients.

Table 2. Patient's demographics according to ASCT2 expression in NGH cohort.

		All (n=104)			AC (n=66)			Non-AC (n=38)
Variable	Total (n=104) (%)	High (n=66)	Low (n=38)	P-value	High (n=36)	Low (n=30)	P-value	High (n=30)	Low (n=8)	P-value
Age
⩽65 years	31	23	8	0.182	18	7	0.041	5	1	>0.999
>65 years	73	43	30		18	23		25	7
Sex
Male	64	46	18	0.035	19	12	0.332	27	6	0.279
Female	40	20	20		17	18		3	2
Smoking
Yes	66	45	21	0.209	17	14	>0.999	28	7	0.518
No	38	21	17		19	16		2	1
p-Stage
I or II	80	44	36	0.001	20	30	<0.001	24	6	>0.999
III or IV	24	22	2		16	0		6	2
T factor
T1-2	93	55	38	0.006	27	30	0.003	28	8	>0.999
T3-4	11	11	0		9	0		2	0
N factor
N0	71	40	31	0.030	18	25	0.009	22	6	>0.999
N1-2	33	26	7		18	5		8	2
Histology
AC	66	36	30	0.019	—	—	—	—	—	—
Non-AC	38	30	8
Lymphatic permeation
Positive	59	44	15	0.008	27	12	0.006	17	3	0.438
Negative	45	22	23		9	18		13	5
Vascular invasion
Positive	57	44	13	0.002	17	8	0.126	27	5	0.094
Negative	47	22	25		19	22		3	3
CD98
High	57	46	11	<0.001	20	4	<0.001	26	7	>0.999
Low	47	20	27		16	26		4	1
Ki-67
High	46	42	10	<0.001	13	5	0.099	29	5	0.024
Low	58	24	28		23	25		1	3
CD34
High	47	38	9	0.001	22	5	<0.001	16	4	>0.999
Low	57	28	29		14	25		14	4
p-mTOR
High	41	30	11	0.144	26	11	0.006	4	0	0.559
Low	63	36	27		10	19		26	8

Abbreviations: AC=adenocarcinoma; ASCT2=ASC amino-acid transporter 2; NGH=Nishi-Gunma Hospital; non-AC=non-adenocarcinoma; p-mTOR=phosphorylation of mammalian target of rapamycin; p-stage=pathological stage.

Bold entries show statistically significant difference.

Correlation between ASCT2 expression and different variables

On the basis of Spearman's rank correlation, ASCT2 was significantly correlated with CD98 (r=0.455, P<0.001), Ki-67 (r=0.413, P<0.001), MVD (r=0.482, P<0.001), and p-mTOR (r=0.148, P=0.133) in all patients (n=104) from the NGH cohort (Supplementary Table A1). There was also a close correlation with p-mTOR in the AC patients, but not in the non-AC patients. We also validated the correlation between ASCT2 expression and these markers in the GUH cohort (n=204). Consistent with the NGH cohort, ASCT2 expression was positively correlated with CD98 (r=0.425, P<0.001), Ki-67 (r=0.475, P<0.001), CD34 (r=0.496, P<0.001), and p-mTOR (r=0.140, P=0.045). Expression of ASCT2 was significantly correlated with CD98, Ki-67, MVD, and mTOR in AC patients (n=142), and with p-mTOR and MVD in non-AC (n=62) subjects.

Patient mortality

In the NGH cohort, the 5-year survival rate and median survival time (MST) for all patients were 51% and not reached, respectively. The results of univariate and multivariate analyses are shown in Table 3, whereas Figure 2 shows the Kaplan–Meier survival curve of patients with positive and negative ASCT2 expression. Patient survival was significantly associated with sex, smoking history, disease stage, histology, lymphatic permeation, vascular invasion, ASCT2, and Ki-67 LI, as assessed by a univariate analysis. A multivariate analysis confirmed that disease stage and ASCT2 were independent prognostic factors for poor PFS and OS. Expression of ASCT2 was also an independent prognostic indicator for poor outcome in patients with AC.

Table 3. Univariate and multivariate analysis of overall survival and progression-free survival in NGH cohort.

	Overall survival			Progression-free survival
	Univariate analysis		Multivariate analysis	Univariate analysis		Univariate analysis
Variables	5-Year survival rate (%)	HR 95% CI P-value	HR 95% CI P-value	5-year survival rate (%)	HR P-value	HR (95% CI) P-value
Age		0.959			1.640
⩽65 years	46	0.513–1.796		33	0.884–3.042
>65 years	54	0.897		55	0.116
Sex		2.322	1.326		1.978
Male	44	1.284–4.200	0.819–2.174	40	1.130–3.463	2.074 (0.857–5.031)
Female	66	0.005	0.255	61	0.017	0.106
Smoking		1.821	0.898		1.314
Yes	47	1.001–3.299	0.316–2.359	46	0.746–2.313	1.598 (0.646–3.713)
No	61	0.048	0.834	53	0.344	0.302
p-Stage		6.605	2.677		9.022
I or II	62	2.929–14.89	1.394–5.079	59	4.027–20.21	2.935 (1.574–5.420)
III or IV	10	<0.001	0.004	14	<0.001	<0.001
Histology		1.985	1.274		1.388
AC	57	1.047–3.763	0.648–2.533	51	0.768–2.507	0.965 (0.509–1.835)
Non-AC	42	0.035	0.482	44	0.277	0.915
Lymphatic permeation		2.517			2.543
Positive	35	1.397–4.534		34	1.452–4.454
Negative	71	0.021		67	0.001
Vascular invasion		3.550			2.834
Positive	31	1.968–6.405		30	1.619–4.959
Negative	78	<0.001		70	<0.001
ASCT2		3.137			3.183
High	33	1.729–5.690	2.753 (1.222–7.071)	30	1.814–5.585	2.861 (1.324–6.896)
Low	81	<0.001	0.013	78	<0.001	0.009
CD98		1.495			1.333
High	47	0.832–2.686		44	0.765–2.325
Low	58	0.178		54	0.310
Ki-67		1.887			1.504
High	44	1.045–3.407		41	0.861–2.626
Low	60	0.035		55	0.151
CD34		1.379			1.362
High	48	0.763–2.492		40	0.778–2.381
Low	56	0.287		55	0.279
p-mTOR		1.079			1.168
High	50	0.597–1.948		46	0.663–2.506
Low	53	0.802		49	0.590

Abbreviations: 95% CI=95% confidence interval; AC=adenocarcinoma; ASCT2=ASC amino-acid transporter 2; CI=confidence interval; HR=hazard ratio; NGH=Nishi-Gunma Hospital; non-AC=non-adenocarcinoma; p-mTOR=phosphorylation of mammalian target of rapamycin; p-stage=pathological stage.

Bold entries show statistically significant difference.

Figure 2.

Kaplan–Meier analysis of OS correlated with ASCT2 expression in the NGH and GUH cohorts. A statistically significant difference in OS was observed between the patients with positive and negative tumour expression of ASCT2 in all patients in the NGH (A) and GUH (D) cohorts. When OS was separated by histology, a statistically significant difference was identified in patients with AC in the NGH (B) and GUH (E) cohorts, but not in those with non-AC in NGH (C) and GUH (F).

We next sought to validate the association between ASCT2 expression and survival in the GUH cohort. In the validation cohort (GUH series), the 5-year survival rate and MST for all patients were 69% and 3491 days, respectively. We compared the OS after surgery between the NGH and GUH cohorts, and found that the OS in the GUH cohort was significantly longer than in the NGH cohort (P=0.007). There was also a (nearly significant) association between positive ASCT2 expression and poor outcome (Figure 2; Table 4). In GUH cohort, we did multivariate analysis using the same prognostic variables in NGH cohort. A multivariate analysis indicated that disease stage was an independent prognostic factor for poor outcome in all patients with NSCLC (Table 4). Survival was then examined in relation to histological sub-type. In patients with AC, tumour stage and ASCT2 expression were independent predictors of poor OS in a multivariate analysis (Table 5). In contrast, ASCT2 expression was not associated with poor prognosis in patients with SQC.

Table 4. Univariate and multivariate analysis of overall survival and progression-free survival in GUH cohort.

	Overall survival			Progression-free survival
	Univariate analysis		Multivariate analysis	Univariate analysis		Multivariate analysis
Variables	5-Year survival rate (%)	HR P-value	HR (95% CI) P-value	5-Year survival rate (%)	HR P-value	HR (95% CI) P-value
Age		0.605			0.743
⩽65 years	76	0.359–0.992		65	0.473–1.167
>65 years	66	0.055		57	0.197
Sex		1.343			1.128
Male	67	0.835–2.158	0.922 (0.633–1.316)	59	0.732–1.737	1.130 (0.807–1.553)
Female	76	0.264	0.665	60	0.585	0.468
Smoking		1.606			1.544
Yes	65	0.998–2.584	0.895 (0.610–1.328)	55	0.999–2.384	1.242 (0.871–1.751)
No	76	0.062	0.578	67	0.051	0.227
p-Stage		5.981			13.26
I or II	78	3.213–11.13	3.401 (2.059–5.569)	72	7.147–24.62	2.175 (1.730–2.725)
III or IV	38	<0.001	<0.001	16	<0.001	<0.001
Histology		1.366			1.252
AC	71	0.809–2.306	1.029 (0.557–1.901)	61	0.780–2.009	0.950 (0.721–1.252)
Non-AC	66	0.323	0.926	57	0.351	0.715
Lymphatic permeation		3.232			3.574
Positive	52	1.985–5.264		39	2.280–5.602
Negative	83	<0.001		74	<0.001
Vascular invasion		3.624			3.748
Positive	50	2.170–6.051		37	2.335–6.018
Negative	80	<0.001		72	<0.001
ASCT2		1.657			1.551
High	61	1.035–2.654	1.179 (0.911–1.534)	41	1.008–2.388	1.093 (0.868–1.382)
Low	77	0.035	0.209	54	0.046	0.447
CD98		1.541			1.710
High	63	0.925–2.569		48	1.073–2.724
Low	73	0.137		65	0.024
Ki-67		1.748			1.686
High	61	1.083–2.823		49	1.091–2.607
Low	76	0.031		68	0.018
CD34		1.876			1.642
High	62	1.170–3.010		51	1.067–2.526
Low	77	0.012		68	0.024
p-mTOR		1.475			2.088
High	61	0.868–2.505		42	1.269–3.437
Low	73	0.130		66	0.004

Abbreviations: 95% CI=95% confidence interval; AC=adenocarcinoma; ASCT2=ASC amino-acid transporter 2; GUH=Gunma University Hospital; HR=hazard ratio; non-AC=non-adenocarcinoma; p-mTOR=phosphorylation of mammalian target of rapamycin; p-stage=pathological stage.

Bold entries show statistically significant difference.

Table 5. Univariate and multivariate analysis of OS and PFS in AC patients (GUH cohort).

	Overall survival			Progression-free survival
	Univariate analysis		Multivariate analysis	Univariate analysis		Multivariate analysis
Variables	5-Year survival rate (%)	P-value	HR (95% CI) P-value	5-Year survival rate (%)	P-value	HR (95% CI) P-value
Age
⩽65 years	78	0.075		68	0.175
>65 years	67			56
Sex
Male	67	0.267	0.891 (0.592–1.324)	58	0.509	1.056 (0.732–1.506)
Female	74		0.665	63		0.766
Smoking
Yes	63	0.046	0.898 (0.603–1.354)	52	0.038	1.196 (0.823–1.719)
No	77		0.578	68		0.343
p-Stage
I or II	82	<0.001	2.186 (1.614–2.967)	75	<0.001	2.175 (1.730–2.725)
III or IV	35		<0.001	15		<0.001
Lymphatic permeation
Positive	46	<0.001		32	<0.001
Negative	86			78
Vascular invasion
Positive	44	<0.001		27	<0.001
Negative	84			77
ASCT2
High	59	0.009	1.424 (1.057–1.929)	48	0.024	1.205 (0.919–1.583)
Low	79		0.012	69		0.177
CD98
High	61	0.270		37	0.021
Low	73			66
Ki-67
High	51	0.001		37	0.002
Low	78			69
CD34
High	58	0.006		43	0.013
Low	77			69
p-mTOR
High	64	0.243		42	0.004
Low	75			70

Abbreviations: 95% CI=95% confidence interval; AC=adenocarcinoma; ASCT2=ASC amino-acid transporter 2; GUH=Gunma University Hospital; HR=hazard ratio; OS=overall survival; PFS=progression-free survival; p-mTOR=phosphorylation of mammalian target of rapamycin; p-stage=pathological stage.

Bold entries show statistically significant difference.

Discussion

This is the first report to evaluate the prognostic significance of ASCT2 expression in patients with surgically resected NSCLC. Our data clearly demonstrate that ASCT2 expression was an independent prognostic marker for poor outcome after surgery in patients with NSCLC, particularly AC. Although the expression of ASCT2 was increased significantly in non-AC patients compared with AC patients, ASCT2 in AC patients was more closely associated with disease stage, lymphatic permeation, vascular invasion, CD98, cell proliferation, angiogenesis, and mTOR phosphorylation. Moreover, two independent cohorts demonstrated that ASCT2 was an independent predictor of poor outcome in AC patients. Our validated data suggest that ASCT2 has an important role in the aggressiveness and metastasis of lung cancer, particularly AC.

Only two previous studies reported enhanced expression of ASCT2 in primary human colorectal AC and prostate cancer, suggesting a close relationship between its expression and poor prognosis (Whitte et al, 2002; Li et al, 2003). Therefore, further study is warranted to investigate the clinical significance of ASCT2 expression in other human cancers. Our study focussed on the clinicopathological significance of ASCT2 expression in patients with lung cancer. Importantly, our study included validating data from an independent cohort, and evaluated the expression and activation of the mTOR signalling pathway, which is related to protein synthesis. Previously, we demonstrated that LAT1 is required for the upregulation of mTOR in lung cancer, which was supported by in vitro and in vivo data (Imai et al, 2010; Kaira et al, 2011). Fuchs et al (2007) reported that LAT1 provides essential amino acids for tumour cell growth via mTOR-stimulated translation, and that ASCT2 maintains the cytoplasmic amino-acid pool necessary to promote LAT1 function. Therefore, they demonstrated that both LAT1 and ASCT2 are highly expressed in human cancers, and that there is reciprocal regulation among LAT1, ASCT2, and mTOR. Recent studies demonstrated that the inhibition of amino-acid transporters reduces the p-mTOR, p70 ribosomal S6 kinase, and 4E-binding protein-1. This leads to the induction of apoptosis by depleting the intracellular amino acids required for cancer growth, and induces a cell-cycle arrest at G1 phase (Liu et al, 2004; Yamauchi et al, 2009; Imai et al, 2010; Kim et al, 2010). Because the p-mTOR is closely related to the survival and metastasis of cancer cells, the inhibition of amino-acid transporters such as LAT1 or ASCT2 may suppress tumour growth by decreasing mTOR phosphorylation. However, additional studies are needed to investigate the mechanism by which the inhibition of ASCT2 expression inhibits tumour growth.

We found that ASCT2 could be a pathological marker for predicting poor outcome after surgery, and that it was closely associated with tumour cell proliferation and angiogenesis in patients with AC, but not in non-AC patients (predominantly SQC). However, the reasons for the differential effects and levels of ASCT2 protein expression between AC and non-AC patients remain unclear. Expression of LAT1 is significantly higher in patients with SQC than in those with AC (Kaira et al, 2008). The expression of ASCT2 analysed by histological sub-type is similar to that of LAT1 (Kaira et al, 2008). In our study, ASCT2 seemed to have an important role in tumour cell proliferation and angiogenesis in AC patients, suggesting a close relationship between ASCT2 expression and prognosis. However, little is known about the clinical significance of the expression pattern of ASCT2 in human tumour tissues. Therefore, it is necessary to investigate ASCT2 expression in various types of cancer using human cancer specimens. Presently, clinicopathological studies of ASCT2 expression are ongoing in gastrointestinal cancer, hepatobiliary cancer, multiple myeloma, ovarian tumours, and breast cancer.

There are several limitations to our study. First, the number of non-AC patients included was small, and the histological distribution of non-AC disease was different between the NGH and GUH cohorts, which may have biased our results. The frequency of SQC patients was significantly higher in the GUH cohort (100%, 62 out of 62) than in the NGH cohort (74%, 28 out of 38) (P<0.01). However, a survival analysis of the non-AC patients seemed to give comparable results in the two cohorts. Second, the frequency of ASCT2 expression in the GUH cohort was significantly lower than in the NGH cohort. Therefore, tumour aggressiveness and prognosis after surgery may be different between these cohorts. In addition, there was a significant difference in lymphatic permeation, vascular invasion, and biomarker expression (CD98 and p-mTOR) between the NGH and GUH cohorts. Although we cannot describe the detailed reason for these differences, the tumour characteristics may be more aggressive in NGH than in GUH, considering that the expression of ASCT2 has a significant relationship with lymphatic permeation, vascular invasion, CD98, and p-mTOR. The present study showed that the expression of ASCT2 was closely associated with lymphatic permeation, vascular invasion, and cell proliferation (Ki-67). Therefore, these factors were excluded from the multivariate analysis to assess ASCT2 as an independent prognostic factor and also to resolve confounding issue. Finally, median survival was not reached for the NGH cohort. In this cohort, five patients were lost to follow-up. The NGH cohort may have a potential for selection bias, because of the issues with loss to follow-up in this cohort. Moreover, the sample size was markedly different between NGH and GUH cohort. These findings may be possible reasons for this discrepancy for survival analysis.

In conclusion, the expression of ASCT2 is a validated predictive marker for poor prognosis in patients with AC, and is significantly correlated with tumour aggressiveness, cell proliferation, angiogenesis, and mTOR phosphorylation. The inhibition of ASCT2 could be a future therapeutic strategy for lung cancer. However, additional studies are needed to assess the biological significance of inhibiting ASCT2 in human cancer cells.

The authors declare no conflict of interest.